EP1664350A2 - Method for small volume nucleic acid synthesis - Google Patents
Method for small volume nucleic acid synthesisInfo
- Publication number
- EP1664350A2 EP1664350A2 EP04789156A EP04789156A EP1664350A2 EP 1664350 A2 EP1664350 A2 EP 1664350A2 EP 04789156 A EP04789156 A EP 04789156A EP 04789156 A EP04789156 A EP 04789156A EP 1664350 A2 EP1664350 A2 EP 1664350A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cdna
- sample
- rna
- hybridization
- array
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Definitions
- the present invention relates to an improved method for nucleic acid synthesis.
- cDNA or "Complementary DNA” is a DNA copy made off of a messenger RNA (mRNA) or other type of RNA molecule template. Synthesis of the cDNA molecule from the original mRNA is accomplished using an enzyme known as Reverse Transcriptase (RT), which is .an RNA dependent DNA polymerase. Reverse Tr.anscriptase was initially discovered in connection with retroviruses, .and can be obtained via purification from such a virus, such as avian myoblastosis virus
- a library can be constructed of cD ⁇ A molecules complementary to the cellular mR ⁇ A. That cD ⁇ A library can then be used for various experimental purposes. For example, a cD ⁇ A library formed from a particular tissue type can used for gene expression analysis, i.e. to provide information regarding the expression of nucleic acids in the initial sample.
- Gene expression analysis may be of use in a variety of applications, including, for example, the identification of novel expression of genes, the correlation of gene expression to a particular phenotype, screening for disease predisposition, and identifying the effect of a particular agent on cellular gene expression, such as in toxicity testing and screening for new drug compounds.
- total (or messenger) R ⁇ A is extracted from the desired sample of cells.
- Copies of complementary D ⁇ A (cD ⁇ A) are generated from the R ⁇ A through reverse transcription.
- the cD ⁇ A copies are tagged with a marker or label such as a fluorescent marker and broken up into short fragments.
- microarrays operate on a similar principle: a substantially planar substrate such as a glass slide or a silicon chip or nylon membrane is coated with a grid of tiny spots of about 20 to 100 microns in diameter. Each spot (i.e. feature) contains millions of copies of a short sequence of DNA or nucleotides; a computer keeps track of the location of each sequence on the substrate, allowing the user to conduct thousands of miniature test-tube like reactions simultaneously. After tagging of the cDNA copies, the tagged fragments are washed over the microarray and left overnight, to allow the tagged fragments to hybridize with the DNA attached to the microarray. After hybridization, the features on the microarray that have paired with the fluorescent cDNA emit a fluorescent signal that can be viewed with a
- ethanol precipitation An illustrative protocol for ethanol precipitation to enable cDNA concentration is as follows:
- ethanol precipitation is a traditional and accepted method for nucleic acid concentration, unfortunately, it may lead to variable results due to partial or complete loss of the pelleted cDNA or incomplete re-solubilization of the precipitated cDNA. For example, as can be seen above, problems may occur if the ethanol precipitation procedure is not performed carefully because reverse transcription of small quantities of RNA produces a cDNA pellet that is very small and easily lost during processing or by adherance to the inside ofpipettips.
- An alternate method for concentration of the cDNA pellet is concentration with Microcon® microconcentrators.
- a sample protocol for Microcon® concentration is as follows:
- cDNA samples may be concentrated using the Millipore Microcon® YM-30 Centrifugal Filter Devices (30,000 molecular weight cutoff, Millipore catalog number 42409).
- the following protocol is .an example of a method provided to reduce the volume of the cDNA synthesis reaction from 130 ⁇ l to 3-10 ⁇ l, for hybridization to an .array. (Note: while the following sample protocol is similar to that provided by the manufacturer, it is
- Express Mail Label No. EV 515441881 US 4 includes minor modifications for use with the 3DNA Array 350 kit. Additionally, users of the Microcon YM-30 should evaluate their own centrifuge settings to determine the optimal time and speed settings to yield final volumes of 3-10 ⁇ l).
- IX TE buffer (1 OmM Tris-HCl, pH 8.0/ lmM EDTA)
- sample concentration protocols traditionally utilized prior to application of the cDNA to a microarray require a time consuming extra series of steps after cDNA synthesis. In some cases, these additional steps can decrease performance and the results obtained in the assay.
- Express Mail Label No. EV 515441881 US 6 cDNA which allows application of the cDNA to a microarray without the need for concentration of the cDNA after cDNA synthesis. It is a further object of the present invention to provide a method for synthesis of cDNA, which allows application of the cDNA to a microarray without the need for purification of undesirable molecules from the cDNA sample after cDNA synthesis. It is a further object of the present invention to provide a method for synthesis of cDNA for application to microarrays in a readily automatable fashion.
- a method for improved nucleic acid synthesis.
- the method provides higher sensitivity results from very small quantities of sample materials than provided by traditional methods in the art by eliminating a sample concentration protocol after nucleic acid synthesis.
- the invention is used for the synthesis of cDNA (complementary DNA) from an initial RNA s.amples, such as mRNA from a source of interest.
- the method is used for nucleic acids intended for application to microarrays, for assay of those nucleic acids using hybridization of the synthesized nucleic acids to known molecules affixed to the array.
- the assays are conducted using dendritic nucleic acid reagents.
- capture sequences are used to label the synthesized nucleic acids and/or the nucleic acids on the .array.
- kits may be provided for conducting the methods disclosed herein. Additionally, the processes can also be used for other types of sample preparations for unrelated applications.
- the avoidance of the need for a post-synthesis sample concentration protocol is a significant advantage of the present method, particularly since such protocols can cause excessive loss of sample.
- the method is particular/ useful with small quantity preparations starting with less than one microgram (1000 nanograms) of total RNA or equivalent nucleic acid sample.
- a further significant advantage of the present invention is that it provides a reduction of the time and number of operations required to perform complete cDNA synthesis. This advantage is of particular importance for a variety of contexts and applications, including the needs of research laboratories, diagnostic kits, clinical settings, and so forth.
- Yet a further significant advantage of the invention is that it provides a better consistency of final cDNA yield based on the same input materials, leading to better reproducibility of results.
- Figure 1 is a schematic view of a preferred method in accordance with the present invention.
- the present invention is generally directed to a method for provided for nucleic acid synthesis which avoids the need for post-synthesis sample concentration.
- the invention is particul.arly suitable for nucleic acid synthesis, such as cDNA synthesis, conducted in conjunction with assay on a microarray.
- nucleic acid synthesis such as cDNA synthesis
- a microarray Express Mail Label No. EV 515441881 US 8 of DNA or gene probes fixed or stably associated with the surface of a substantially planar substrate ("a microarray") is contacted with a sample of target nucleic acids under hybridization conditions sufficient to produce a hybridization pattern of complementary probe/t.arget complexes.
- a v.ariety of different microarrays which may be used are known in the art.
- the hybridized samples of nucleic acids are then targeted by labeled probes and hybridized to produce a detectable signal corresponding to a particular hybridization pattern.
- the individual labeled probes hybridized to the target nucleic acids are all capable of generating the same signal of known intensity. Thus, each positive signal in the microarray can be "counted” in order to obtain quantitative information about the genetic profile of the t.arget nucleic acid sample.
- the DNA or gene probes of the microarrays which are capable of sequence specific hybridization with target nucleic acid may be polynucleotides or hybridizing analogues or mimetics thereof, including, but not limited to, nucleic acids in which the phosphodiester linkage has been replaced with a substitute linkage group, such as phophorothioate, methylimino, methylphosphonate, phosphoramidate, guanidine and the like, nucleic acids in which the ribose subunit has been substituted, e.g. hexose phosphodiester; peptide nucleic acids, and the like.
- a substitute linkage group such as phophorothioate, methylimino, methylphosphonate, phosphoramidate, guanidine and the like
- nucleic acids in which the ribose subunit has been substituted e.g. hexose phosphodiester
- peptide nucleic acids and the like.
- the length of the probes will generally range from 10 to 1000 nucleotides, although the present invention is not limited to probes of such lengths.
- the probes will be oligonucleotides having from 15 to 150 nucleotides and more usually from 15 to 100 nucleotides.
- the probes will be longer, usually ranging in length from 150 to 1000 nucleotides, where the polynucleotide probes may be single or double str.anded, usually single stranded, and may be PCR fragments amplified from cDNA.
- the DNA or gene probes on the surface of the substrates will preferably correspond to known genes of the physiological source being analyzed and be positioned on the microarray at a known location so that positive hybridization events may be correlated to expression of a particular gene in the physiological source from which the target nucleic acid sample is derived. Because of the manner in which the target nucleic acid sample is generated, as described below, the microarrays of gene probes will generally have sequences that are complementary to the non-template str.ands of the gene to which they correspond.
- the substrates with which the gene probes are stably associated may be fabricated from a variety of materials, including plastic, ceramic, metal, gel, membrane, glass, and the like.
- the microarrays may be produced according to any convenient and conventional methodology, such as preforming the gene probes and then stably associating them with the surface of the support or growing the gene probes directly on the support.
- a number of different microarray configurations and methods for their production are known to those of skill in the art, one of which is described in Science, 283, 83, 1999, the content of which is incorporated herein by reference.
- a desired micrcarray having the probe nucleic acid sequences stably affixed thereto.
- a sample is provided having the target molecules of interest for study.
- the target molecules are labelled for detection, the term "label" is used herein to refer to agents that are capable of providing a detectable signal, either directly or through interaction with one or more additional members of a signal producing system.
- the label is one which preferably does not provide a variable signal, but instead provides a constant and reproducible signal over a given period of time.
- the target molecules can be labelled prior to or after application of target to the array, although prior labelling is generally preferred.
- a very sensitive signal generating method is used, such as a dendrimer or another comparably sensitive signal generating methods, e.g. relative light scatter detection using nanogold labels, such as those of Genicon Inc. / Invitrogen.
- dendritic nucleic acid molecules are particul ⁇ ly preferred for their detection capabilities (although .any type of labelled molecules of suitable sensitivity can be utilized with the inventions disclosed herein).
- Dendritic nucleic acid molecules, or dendrimers are complex, highly branched molecules, comprised of a plurality of interconnected natural or synthetic monomeric subunits of double-str.anded DNA. Dendrimers .are described in greater detail in Nilsen et al., Dendritic Nucleic Acid Structures, J. Theor.
- Dendrimers comprise two types of single-str.anded hybridization "arms" on the surface which are used to attach two key functionalities.
- a single dendrimer molecule may have at least one hundred arms of each type on the surface.
- One type of arm is used for attachment of a specific targeting molecule to establish target specificity .and the other is used for attachment of a label or marker.
- the molecules that determine the target and labeling specificities of the dendrimer are attached either as oligonucleotides or as oligonucleotide conjugates.
- a dendrimer molecule may be configured to act as a highly labeled, target specific probe.
- the prepared mixture is formulated in the presence of a suitable buffer to yield a dendrimer hybridization mixture contmning dendrimers with fluorescent labels attached to one type of "arm”, and with oligonucleotides attached to another type of ".arm", complementary to the capture sequences of the RT primer bound cDNA fragments.
- An oligonucleotide designed to block non-specific interaction of the cDNA or the dendrimer to the nucleic acid spotted on the array surface can also be added at this time; blocking
- oligonucleotides containing the multiplicities of the s.ame nucleic acid base may be used for blocking long stretches of the same complementary base found on the cDNA derived from the RNA sample and the nucleic acid probes on the microarray surface.
- the complementary sequences to the capture sequence on the Cy3® RT primer and the Cy5® RT primer are ligated, separately, to the purified dendritic core material as prepared by the previously described methods (see Nilson et al., supra, and U.S. Pat. Nos. '270, '904, and '973, supra.).
- Thirty nucleotide long oligonucleotides complementary to the outer arms of a four-layer dendrimer having a 5' Cy3® or Cy5® are then synthesized. (Oligos etc., Inc., Wilsonville, OR).
- Cy3® and Cy5® oligonucleotides are then hybridized and covalently cross-linked to the outer surface of the corresponding dendrimers, respectively. Excess capture and fluorescent labeled oligonucleotides are then removed through techniques such as size exclusion chromatography and density gradient ultracentrifugation.
- the concentration of dendrimer is determined by measuring the optical density of the purified material at 260 nm on a UN/Vis spectrometer. The fluorescence is measured at optimal signal/noise wavelengths using a fluorometer (FluoroMax, SPEX Industries). Cy3 is excitable at 542 nm and the emission measured at 570 nm. Cy5 is excitable at 641 nm and the emission at 676 nm.
- a dendrimer is utilized having approximately 850 fluorescent dyes on each molecule, such as the dendrimers available in the Genisphere, Inc. 3D ⁇ A Array 900 labeling kit.
- prior dendrimers having approximately three hundred dyes can be utilized, or dendrimers having more than 500 fluorescent dyes.
- RNA required for an assay is reduced, allowing the use of smaller volumes of initial sample.
- the present invention can be easily conducted using 0.25 - 1 microgram of total RNA, or, as low as 100 nanograms of total RNA (0.1 micrograms); or
- RNA poly A RNA
- a dendrimer having approximately 850 or more fluorescent dyes is preferably utilized to obtain these improved results.
- sensitivity of detection improves in the art (e.g. using improved dendrimers or other improved labelling and signal molecules)
- smaller RNA samples may be assayed using the present invention as well.
- a strategy is preferably used (a "two step method") that employs successive hybridization steps where the reverse transcribed cDNA is applied to the array for a sufficiently long period to allow hybridization thereto, with hybridization of the cDNA molecules to target immobilized probes being followed by a washing procedure where the unbound cDNA and excess RT primer is removed from the array.
- the cDNA preferably has a capture sequence incorporated thereto for binding to a dendritic nucleic acid having a label capable of generating a detectable signal, as disclosed below.
- the fluorescently labeled dendrimer molecule (or another molecule capable of binding to the capture sequence incorporated into the cDNA) is subsequently applied to the washed array and hybridizes to the cDNA associated capture sequence during this second hybridization. Excess dendrimer is washed away during a secondary washing procedure and the arrays are scanned to detect signal generated by the label molecule.
- temperature cycling can be used to selectively control hybridization between the t.arget nucleic acid and the micro.array, and hybridization between the capture reagent and the microarray (preferably cDNA - microarray hybridization and cDNA - dendrimer hybridization, respectively).
- hybridization can be carefully controlled such that cDNA initially hybridizes only to the micro.array, with subsequent hybridization of cDNA to the dendrimer.
- This procedure can be used to improve the kinetics of hybridization of each of the two components, i.e. target nucleic acid to probe, and capture reagent to target nucleic acid. Further details regarding use of such temperature cycling are provided in U.S. Nonprovisional Application Serial No.
- the nucleic acid synthesized will generally be DNA that has been reverse transcribed from RNA derived from a naturally occurring source, where the RNA may be selected from the group consisting of total RNA, poly(A) + RNA, .amplified RNA and the like.
- the initial RNA source may be present in a variety of different samples, where the sample will typically be derived from a physiological source.
- the physiological source may be derived from a variety of sources, with physiological sources of interest including sources derived from single celled organisms such as yeast or bacteria, and multicellular organisms, including plants and animals, particularly mammals, where the physiological sources from multicellular organisms may be derived from particular organs or tissues of the multicellular organism, or from isolated cells derived therefrom.
- physiological sources of interest including sources derived from single celled organisms such as yeast or bacteria, and multicellular organisms, including plants and animals, particularly mammals, where the physiological sources from multicellular organisms may be derived from particular organs or tissues of the multicellular organism, or from isolated cells derived therefrom.
- the physiological source may be subjected to a number of different processing steps, where such known processing steps may include tissue homogenation, cell isolation and cytoplasmic extraction, nucleic acid extraction, poly A tailing, and the like.
- RNA isolating RNA from cells, tissues, organs or whole organisms are known to those of ordin.ary skill in the an .and are described, for example, in Maniatis et al., Molecular Cloning: A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory Press, 1989, and in Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 1998, both of which are fully incorporated herein by reference.
- the sample mRNA is preferably reverse transcribed into a target nucleic acid in the form of a cDNA, by hybridizing an oligo(dT) primer, or RT primer, to the mRNA under conditions sufficient for enzymatic extension of the hybridized primer.
- the primer will be sufficiently long to provide for efficient hybridization to the mRNA tail, where the region will typically range in length from 10 to 25 nucleotides, usually 10 to 20 nucleotides, and more usually from 12 to 18 nucleotides.
- the standard primers as used in the present invention further include "capture sequence" nucleotide portions.
- the preferred capture sequences referred to herein are Cy3® RT primer capture sequences (Oligos etc., Inc, Wilsonville, OR) or Cy5® RT primer capture sequence (Oligos etc., Inc, Wilsonville, OR), as disclosed for example in International Application No.
- the capture sequences should be attached to the 5' end of the corresponding custom oligonucleotide primer. In this manner, the custom primer replaces the standard RT primer. Since the present invention is devised for use with the st.and.ard RT primer, some modifications may be required when substituting a custom primer. Such modifications are known to those of ordinary skill in the art and may include adjusting the amount and mixture of primers based on the amount and type of RNA s.ample used.
- the primer carries a capture sequence comprised of a specific sequence of nucleotides, as described above. The capture sequence is complementary to the oligonucleotides attached to the arms of dendrimer probes which further carry at least one label.
- Such complementary oligonucleotides may be acquired from any outside vendor and may also be acquired as labeled moieties.
- the label may be attached to one or more of the oligonucleotides attached to the arms of the dendrimer probe, either directly or through a linking group, as is known in the an.
- the dendrimer probes are labeled by hybridizing and cross-linking Cy3® or Cy5® labeled oligonucleotides to the dendrimer arms.
- the Cy3® or Cy5® labeled oligonucleotides are complementary to the Cy3® or Cy5® RT primer capture sequences, respectively.
- the primer is contacted with the RNA in the presence of a reverse transcriptase enzyme, and other reagents necessary for primer extension under conditions sufficient for inducing first strand cDNA synthesis.
- a reverse transcriptase enzyme e.g., a reverse transcriptase enzyme, possessing reverse transcriptase activity can be used for the first strand cDNA synthesis step.
- suitable DNA polymerases include the DNA polymerases derived from organisms selected from the group consisting of a thermophilic bacteria and archaebacteria, retroviruses, yeasts, Neurosporas, Drosophilas, primates and rodents.
- Suitable DNA polymerases possessing reverse transcriptase activity may be isolated from an organism, obtained commercially or obtained from cells which express high levels of cloned genes encoding the polymerases by methods known to those of skill in the art, where the particular manner of obtaining the polymerase will be chosen based primarily on factors such as convenience, cost, availability and the like. The order in which the reagents are combined may be modified as desired.
- the cDNA synthesis protocol involves combining total RNA or poly(A) + RNA (mRNA), with RT primer .and RNase free water to yield the RNA-RT primer mix.
- mRNA poly(A) + RNA
- RT primer .and RNase free water to yield the RNA-RT primer mix.
- very small quantities of initial RNA can be utilized, as discussed below.
- RNA-RT primer mixture is then mixed and microfuged to collect the contents at the bottom of the microfuge tube.
- the RNA-RT primer mixture is then heated at a suitable temperature (e.g. 80 degrees Celsius) for ten minutes and immediately transferred to ice.
- a suitable temperature e.g. 80 degrees Celsius
- RT buffer, DTT (dithiothreitol), RNAse inhibitor, dNTP mix, and reverse tr.anscriptase enzyme are combined with RNase free water (the Reaction Master Mix). This combination is gently mixed (but not vortexed) and microfuged briefly to collect the contents at the bottom of the microfuge tube to yield a reaction mixture.
- RNA-RT primer mixture is then mixed with the Reaction Master Mix and incubated at a suitable temperature (e.g. about 42 degrees Celsius) for a period of time sufficient for forming the first strand cDNA primer extension product, which usually takes about 2 hours.
- a suitable temperature e.g. about 42 degrees Celsius
- the reaction is stopped using 1.0M NaOH/100 mM EDTA, and then incubated at a suitable temperature (e.g. 65 degrees Celsius) to denature the DNA/RNA hybrids .and degrade the RNA.
- the reaction is then neutralized with 2M Tris-HCl (pH 7.5).
- the cDNA is applied directly to the .array for hybridization thereto without post-synthesis concentration of the cDNA.
- the mixture obtained above is directly added to the microarray and incubated at a second hybridization temperature and for a sufficient time to allow the cDNA to bind to the microarray.
- Suitable hybridization conditions are well known to those of skill in the .art and reviewed in Maniatis et al, supra, where conditions may be modulated to achieve a desire specificity in hybridization.
- a blocking LNA oligonucleotide can be used to reduce non-specific binding between the cDNA and the array, as discussed in International Application No. PCTUS02/027799 filed 03 September 2002, International Publication No. WO 03/020902 A2, which is fully incorporated herein by reference.
- the array is then washed to reduced background on the array (e.g. caused by free RT primer not incorporated into cDNA molecules).
- a label molecule (preferably a dendrimer carrying a desired label) is then applied to the .array for hybridization of the label to the capture sequence of the cDNA to provide a detectable signal.
- a washing step is employed in which unhybridized complexes .are purged from the microarray, thus leaving behind a visible, discrete pattern of hybridized cDNA-dendrimer probes bound to the micro.array.
- wash solutions and protocols for their use are known to those of skill in the art and may be used. The specific wash conditions employed will necessarily depend on the specific nature of the signal producing system that is employed, and will be known to those of skill in the an familiar with the particular signal producing system employed.
- the resultant hybridization pattern of labeled cDNA fragments may be visualized or detected in a variety of ways, with the particular manner of detection being chosen based on the particular label of the cDNA, where representative detection means include scintillation counting, autoradiography, fluorescence measurement, calorimetric measurement, light emission measurement and the like.
- the resultant hybridization pattern is detected.
- the intensity or signal value of the label will be not only be detected but quantified, by which is meant that the signal from each spot of the hybridization will be measured.
- the hybridization pattern can be used to determine quantitative and qualitative information about the initial RNA sample. For example, information can be obtained regarding the genetic profile of the labeled target nucleic acid sample that was contacted with the micro.array to generate the hybridization pattern. From this data, one can also derive information about the physiological source from which the target nucleic acid sample was derived, such as the types of genes expressed in the tissue or cell which is the physiological source, as well as the levels of expression of each gene, particularly in quantitative terms. Where one uses the subject methods in comparing target nucleic acids from two or more physiological sources, the hybridization patterns may be compared to identify differences between the patterns. Where microarrays in which each
- Express Mail Label No. EV 515441881 US 17 of the different probes corresponds to a known gene
- any discrepancies can be related to a differential expression of a particular gene in the physiological sources being compared.
- the subject methods find use in differential gene expression assays, where one may use the subject methods in the differentia expression analysis of: diseased and normal tissue, e.g. neoplastic and normal tissue, different tissue or subtissue types; and the like.
- RNA sample can be used directly.
- a suitable capture sequence can be ligated to the RNA using known methods of splicing RNA, such as through enzymatic me.ans.
- a complementary oligonucleotide can be attached to a dendrimer to label the RNA molecule. Further details regarding methods for direct use of RNA without the need for reverse tr-anscription are provided in PCT Application No. PCT/USOl/22818 filed July 19, 2001, which is fully incorporated herein by reference.
- the invention is particularly suitable as for improved synthesis and assay of cDNA using very small quantities of initial starting materials, as the present invention allows the use of less initial RNA s.ample th.an prior methods.
- this cDNA method when partnered with the 3DNA dendrimer technology (or other very sensitive signal generating methods, e.g. relative light scatter detection using nanogold labels, such as those of Genicon Inc. / Invitrogen), this cDNA method is p.articul.arly valuable as it allows for use of total RNA s.amples down to 250 nanograms or less without any need for RNA target amplfication.
- the invention can be easily used with 0.25 -1 microgram of sample, or, if desired with 100 nanograms of initial total RNA sample (0.1 micrograms); or with 1 to 1000 nanograms of poly A RNA (mRNA). This is about 2 orders of magnitude better than direct incorporation methods, which require 20-50 micrograms of total RNA, or 1 to 2.5 microgr,ams of poly A RNA (mRNA) for the s.ame level of sensitivity.
- sensitivity of detection increases in the art (e.g. using improved dendrimers, or dendrimers having additional fluorescent dyes, or other improved signal generating methods)
- smaller samples of RNA can be utilized in conjunction with the present invention as well. Those samples can likewise be applied to the microarray without concentration of the cDNA post- synthesis.
- the invention provides the ability to scale up the reaction and yet still avoid the need for concentration of purification of the final cDNA synthesis.
- a further benefit of the invention is the reduction of non-specific background on microarrays caused directly or indirectly by the presence of high amounts of cDNA, which are avoided by using this method.
- the method provides increased data quality (specifically, the range of differentials in a gene expression experiment), which is likely due to the very small quantity of cDNA used in the array hybridization assay. This is due to the fact that, as opposed to prior methods, in the present invention no concentration is conducted of the cDNA post synthesis. Previous methods generally require concentration of cDNA for using the cDNA on most types of arrays due to the larger sample size required with non-3DNA methods and the small volumes required for the micro-array hybridization.
- a further improvement provided herein is that the present method does not require purification of the cDNA synthesis reaction, which is normally performed for direct dye incorporation cDNA synthesis to remove excess dye and enzyme not incorporated into the cDNA.
- the present invention provides the further advantage of being readily automatable, as opposed to the concentration and purification steps normally used in this context, which are currently difficult to accomplish in an automated fashion or robotically.
- RT Primer may cause non-specific background signal on certain types of arrays (i.e. poly-L-lysine coated slides). This type of background may be reduced by diluting the RT Primer by up to 2.5 fold with Nuclease Free Water prior to its addition to the RNA sample (caution: avoid diluting the primer to less than 2pmole/ ⁇ l as this may cause inefficient cDNA synthesis).
- Reverse transcriptase enzyme and the enzyme' s reaction buffer can be included within that kit or can be purchased separately.
- Superscript II Reverse Transcriptase Enzyme (Gibco Cat No. 18064-014 - 10,000 Units @ 200U/ ⁇ l) is recommended.
- the Reaction Master Mix should be formulated to a final volume dependent on the number of cDNA syntheses set up simultaneously. Each cDNA synthesis requires 4.5 ⁇ L of Reaction Master Mix. To reduce pipetting errors, the Reaction Master Mix should contain at least 9 ⁇ L (enough for two cDNA syntheses).
- Reaction Master Mix This is the Reaction Master Mix. (The Reaction Master Mix should be kept on ice until used).
- the following method is an example of a method for synthesis of cDNA for use with microarrays, wherein, in accordance with the present invention, the method of synthesis avoids the need for post-synthesis s.ample concentration.
- the method is designed for use with reagents from Genisphere, Inc., and in p.articular with the Genisphere® 3DNA Array 900 kit (available from Genisphere, Inc. of Montvde, New Jersey .and Hatfield Pennsylvania), which is designed to provide increased sensitivity on micro.arrays when using extremely small quantities of RNA. (The instructions for use of the Array 900 kit provided with the kit are fully incorporated herein by reference).
- the method can be used with other kits or systems, using the method for small volume synthesis disclosed below.
- better sensitivity is achieved through the use of the modified cDNA synthesis protocol of the present invention that eliminates post-synthesis s.ample concentration, which avoids loss of sample during the concentration process.
- Sensitivity can also be further enh.anced by use of a Genisphere® 3DNA Capture Reagent in the form of a dendrimer containing approximately 850 fluorescent dyes and engineered for more efficient hybridization kinetics, and by use of the Genisphere® 2X Enhanced cDNA Hybridization Buffer designed for better hybridization efficiency.
- the Genisphere® 3DNA Array 900 kit is easy to use and is designed for use with arrays printed with oligonucleotides or PCR products (cDNA).
- cDNA oligonucleotides or PCR products
- the fluorescent 3DNA recent will hybridize to the cDNA because it includes a "capture sequence" that is complementary to a sequence on the 5' end of the RT primer.
- the 3DNA Array 900 labeling system provides a more predictable and consistent signal than direct or indirect dye incorporation for two reasons. First, since the fluorescent dye is part of the 3DNA reagent, it does not have to be incorporated during the cDNA preparation. This avoids inefficient hybridization of the cDNA to the .array that results
- Dye incorporation labeling methods can therefore produce labeled genomic DNA.
- the labeled genomic DNA will bind to microarrays, resulting in false positives for negative genes and/or inappropriate and misleading fluorescence levels for array elements simultaneously bound with cDNA produced by reverse transcription of RNA.
- the 3DNA reverse transcription process utilizes unlabeled nucleotides that cannot incorporate any fluorescence into genomic DNA, thus eliminating the possibility of signal contribution from genomic DNA. Because 3DNA labeling differs from dye incorporation labeling in this way, the array pattern produced may vary depending on which labeling method is used. However, in a differential expression experiment, the expression patterns between the two RNA s.amples should be the same regardless of the labeling method, provided the genomic DNA has been eliminated from the samples.
- 3DNA Array 900 Capture Reagent Vial 1 Cy3 / Alexa Fluor 546 (red cap) or Cy5 / Alexa Fluor 647 (blue cap) 3DNA Array 900 Capture Reagent. (Dendrimer probe reagents as described herein labeled with about 850 fluorescent dyes per molecule. Dendrimers labeled with Cy3 (or Alexa Fluor 546) contain the same unique capture sequence which targets the dendrimer only to cDNAs synthesized with primers containing 5 prime sequence
- RT primers 48mers comprising a 3 prime dT(17) and a 5 prime 31mer capture sequence).
- Nial 5 2X Enhanced cD ⁇ A Hybridization Buffer available from Genisphere Inc. of Montvale, New Jersey and Hatfield, Pennsylv.ania
- Nial 9 L ⁇ A TM dT Blocker for use with PCR product (cD ⁇ A) micorarrays
- a dT blocker comprising 36 nucleotides where 13 of the nucleotides .are L ⁇ A (locked nucleic acid, Exiqon AG) residues.
- U.S. Nonprovisional Application Serial No. 10/234,069 filed 9/3/2002 which claims the priority of U.S. Provisional Application Serial No. 60/316,116 filed 8/31/2001, and "Methods for Blocking Nonspecific Hybridizations of Nucleic Acids", Internation Application No. PCT/US02/027799 filed 03 September 2002, International Publication No. WO 03/020902 A2, all of which are fully incorporated herein by reference).
- RT primers for Cy3 / Alexa Fluor 546 (red cap) or Cy5 / Alexa Fluor 647 (blue cap) (RT primers (48mers) comprising a 3 prime dT(17) and a 5 prime 31mer capture sequence)
- Vials 1-11 should be stored at -20°C in the dark. Vial 1 may be kept at 4°C for short-term storage ( ⁇ 1 week).
- a micrcarray commercial or n-house prepared from either oligonucleotides or PCR/cDNA products
- RNA sample greater than or equal to 1 OOng/ ⁇ l
- Poly(A) + RNA sample greater than or equal to 50ng/ ⁇ l
- RNase inhibitor Superase-In, Nial 4
- R ⁇ .ase inhibitor should be added to stored RNA samples suspected of being contaminated with RNases.
- Inhibitor should .also be added during the reverse transcriptase reaction to avoid RNA degradation during cDNA synthesis.
- RNA degradation by RNases all of which are fully incorporated herein by reference: Sambrook, J., Fritsch, E.F., and Maniatis, T.
- the 3DNA Array 900 labeling system will not label genomic DNA, so it is not essential to remove genomic DNA contamination. However, the quantity and quality of the RNA present may be determined more accurately if the genomic DNA is digested away. Also, if the genomic DNA is .allowed to remain in the sample, it may bind to some of the RT enzyme .and make the enzyme unavailable for reverse transcription. RNase-free DNase is recommended for degrading contaminating genomic DNA.
- DNase If DNase is used, it is essential that the DNase be inactivated completely before proceeding with the cDNA synthesis procedure to prevent degradation of the RT Primer.
- Methods for inactivating DNase include phenol-chloroform extraction and use of the RNeasy ® kits from Qiagen. Inactivation of the DNase by high temperature may not completely inactivate the enzyme.
- High-q ⁇ ality RNA will have the following characteristics:
- OD 260/280 ratio will be between 1.9 and 2.1.
- RNA purification to produce such high-quality RNA may be utilized, including, for example, those of Genisphere®).
- Pre-spotted cDNA arrays manufactured by Genomic Solutions, Agilent and Takara do not require special treatment prior to use.
- Pre-spotted oligo arrays manufactured by MWG Biotech require prewashing as described in Appendix E for optimal results. With other purchased arrays, prepare or pre-treat the microarray as described by the manufacturer. For arrays made "in-house", it is recommended that one of the protocols in Appendix D be used for pre-treating the .arrays. These protocols do not require succinic anhydride treatment and on many array types have yielded stronger signal and lower background. (Please note: This protocol is not compatible with Agilent arrays).
- Genisphere recommends use of certain amino-silane coated slides for spotting PCR products (cDNAs), particularly Clontech DNA-Ready Type fl, Corning GAPS II .and UltraGAPS, and Telechem SuperAniine slides. These slides demonstrate good DNA binding when used with 3DNA Array 900 kits.
- Arrays prepared on poly-L-lysine, aldehyde or certain amino-silane (e.g., Corning GAPS) surfaces may require either a prewash or prehybridization step to reduce the background observed after hybridization.
- a prewash or prehybridization step may require either a prewash or prehybridization step to reduce the background observed after hybridization.
- Appendix E or F respectively, for procedures to help reduce background on microarrays.
- Express Mail Label No. EV 515441881 US 28 performed immediately after spotting (or receipt of arrays) and periodically thereafter to establish non-specific background noise characteristics of the arrays and other materials as they age. Also, all solutions used in post-spotting array processing should be tested to assure consistency and minimal contribution to non-specific .array background.
- the Genisphere Array 900 kit includes the following hybridization buffers:
- 2X Enhanced cDNA Hybridization Buffer (VM 5) — for use in the cDNA hybridization step only, if additional sensitivity is desired. This buffer may be used on arrays that tolerate higher temperatures (up to 65 °C). 2. 2X SDS-Based Hybridization Buffer (VM 6)— for use in both the cDNA .and 3DNA hybridization steps, this buffer may be used on arrays that tolerate higher temperatures (up to 65°C). 3. 2X Formamide-Based Hybridization Buffer (Vial 7) — for use in both the cDNA and 3DNA hybridization steps, this buffer is designed for use at lower temperatures due to its higher stringency formulation.
- hybridization buffers be tested to determine which is best for the array type being utilized. Please note that due to the viscous nature of the 2X Enh.anced cDNA Hybridization Buffer (VM 5), a larger hybridization volume may be required under a coverslip due to volume loss when pipetting. Addition ly, the ranges of hybridization temperatures included in this product m.anual are provided as a guide. Genisphere recommends that the optimal hybridization temperature be empirically determined for each lot of microarrays. For example, the poly-L-lysine surface of some arrays may begin to peel off at the hybridization temperature required for use of the VM 5 or 6 buffer. Use Vial 7 buffer as directed if you experience this problem.
- the LNA dT Blocker is a high-performance poly T based blocking reagent designed by Genisphere (patent pending, see, International Application No. PCT/US02/027799 filed 03 September 2002, International Publication No. WO 03/020902 A2, which is fully incorporated herein by reference). It is designed to completely block all poly A sequences present in array features, including control spots containing only poly dA sequences.
- This new blocking reagent contains Locked Nucleic Acid (LNA) nucleotides (a patented ExiqonTM technology) at key positions within the poly dT synthetic strand.
- LNA Locked Nucleic Acid
- the presence of these modified nucleotides stabilizes the hybridization between complementary strands of nucleic acids, thus improving the blocking capacity of the poly dT reagent. See reference 3 below for additional information relating to LNA chemistry.
- average array signal intensity for a blocked array may be lower compared to a non-blocked array, specific signal from reversed transcribed cDNA binding to complementary array elements should not be adversely affected. While a volume of 2 ⁇ l of the LNA dT Blocker (VM 9) is recommended for each hybridization, some arrays may demonstrate better performance if additional LNA dT Blocker is used (3-4 ⁇ l).
- Add additional competitor nucleic acid as required e.g. species specific Cot-1 DNA from Invitrogen.
- Use competitor nucleic acid at 1/10 by mass of input toM RNA i.e. use lOOng of Cot- 1 DNA for every microgram of toM RNA. If too much competitor is used, the signal may be reduced due to nonspecific interactions of the excess competitor with the limited cDNA in the hybridization. Denaturation of Cot-1 DNA and other competitor nucleic acids is recommended (95-100 ° C for 5-10 minutes) prior to addition to the hybridization mix.
- RNA DNA sequence complementary metal-oxide-semiconductor
- the exact amount of RNA required for a given experiment will typically range from 0.25-1.O ⁇ g of .ani ⁇ M toM RNA or 0.5-2.5 ⁇ g of plant toM RNA.
- l ⁇ g of animal toM RNA or 2 ⁇ g of plant toM RNA is recommended as a starting point for cDNA synthesis. Larger or smaller amounts of RNA may be required to achieve optimal results, depending on the qu ⁇ ility of the RNA s.ample and the array.
- RNA Larger quantities of RNA (>2 ⁇ g) may be used for large-scale cDNA synthesis.
- Appendix A details a simple procedure for synthesizing cDNA from 2-50 ⁇ g toM RNA.
- the procedure outlined on page 11 may be scaled up to accommodate larger quantities of toM RNA.
- the larger reaction volume that results may require concentration of your cDNA samples (see Appendix C).
- cDNA prepared using procedures from certain other Genisphere kits may also be used in conjunction with the Array 900 kit.
- the following Genisphere kits contain components for cDNA synthesis that generate cDNA compatible with the Array 900 3DNA Capture Reagents (Vial 1):
- Array 350 (Catalog No. W300100, W300110, W300130, W300140, W300180, and W300184)
- Array 350HS (Catalog No. H300100, H300110, H300130, H300140, H300180, and H300184)
- Array 50 (Version 2) (Catalog No. B100121, B100122, B100171, B100172, B100187, and B100189)
- RNA-RT primer mix 1-5 ⁇ l toM RNA (0.25-1.0 ⁇ g mammalian toM RNA or 0.5-2.5 ⁇ g plant toM RNA) 1 ⁇ l RT Primer (Vial 2, lpmole/ ⁇ l) Add Nuclease Free Water (Vial 10) to a final volume of 6 ⁇ l.
- Reaction Master Mix Prep.are a Reaction Master Mix in a microtube on ice (see table below).
- the Reaction Master Mix should be formulated to a final volume dependent on the number of cDNA syntheses set up simultaneously. Each cDNA synthesis requires 4.5 ⁇ l of Reaction Master Mix. To reduce pipetting errors, the Reaction Master Mix should contain at least 9 ⁇ l.
- Express Mail Label No. EV 515441881 US 32 8. Incubate at 65°C for ten minutes to denature the DNA/RNA hybrids and degrade the RNA.
- l.O ⁇ l COT-1 DNA may also be added if desired (must be denatured at 95-100°C for 10 minutes prior to use).
- the cDNA Hybridization Mix volume may be increased by adding equal volumes of 2X Hybridization Buffer (Vial 5, 6 or 7) and Nuclease Free Water (Vial 10).
- hybridization temperatures recommended in this protocol are intended as a starting point .and should be used as a guide. It may be necessary to adjust the temperatures to meet the stringency requirements dictated by the nature of the nucleic acids spotted on the .array as well as the slide surface chemistry. In particular, increasing the hybridization temperature by 5°C may remove non-specific signal.
- Express Mail Label No. EV 515441881 US 35 Transfer the array to a dry 50mL centrifuge tube, orienting the slide so that any label is down in the tube. Immediately centrifuge without the tube cap for 2 minutes at 800-1000 RPM to dry the slide (any delay in this step may result in high background). Avoid contact with the .array surface.
- wash conditions may be required to achieve optimal array performance. If necessary to reduce background on the .array, it is recommended that the time of some or all of the washes be increased to 15-20 minutes. Agitation during washing may also help to reduce background due to non-specific binding to the surface of the array.
- the Anti-Fade Reagent reduces fading of the fluorescent dyes post hybridization.
- do not use the Anti-Fade Reagent if your arrays are printed on aldehyde-coated slides, as background haze may result. Refreeze the Anti-Fade Reagent after use.
- Cot-1 DNA may also be added if desired (must be denatured at 95- 100°C for 10 minutes prior to use). Note: For single channel expression analysis, use 2.5 ⁇ l of Nuclease Free Water (NM 10) in place of the second 3D ⁇ A Array 900 Capture Reagent.
- NM 10 Nuclease Free Water
- the volume of the 2X Hybridization Buffer (Vial 6 or 7) and Nunclease Free Water (Vial 10) to a volume appropriate for the desired coverslip.
- the final 3DNA Hybridization Mix for a 30 ⁇ l volume would contain:
- the 3DNA Hybridization Mix volume may be increased by adding equal volumes of 2X Hybridization Buffer (Vial 6 or 7) and Nuclease Free Water (Vial 10). Incubate the array for 4-5 hours in a dark humidified chamber at the appropriate hybridization temperature:
- wash conditions may be required to achieve optinM .array performance. If necessary to reduce background on the array, increase the time of some or all of the washes to 15- 20 minutes. Agitation during washing may also help to reduce background due to non-specific binding to the surface of the array.
- IMPORTANT Store the .array in the dark until scanned.
- the fluorescence of the 3DNA reagents, especially Cy5 and Alexa Fluor 647, can diminish rapidly even in ambient light because of oxidation. Please refer to Appendix F for recommendations for reducing the degradation of Cy5/Alexa Fluor 647 when performing micro-array experiments.
- the recommendation is to start by setting the laser at 80% power and either use the "autobalance" feature or the table below to set up the initM scanning p.ar.ameters for proper channel balance. Adjustment of your scanner laser power and photo-multiplier tube (PMT) voltage may be required to b.al.ance the various fluorophore ch.annels. If the PMT setting is set too high, the background observed may be unacceptable. In these instances the PMT setting should be reduced and the laser power should be increased to optimize the signal-to-noise ratio. However, to prevent photobleaching the fluorescent dyes, especially Cy5/Alexa Fluor 647, .after a single scan, avoid setting the laser too high (>90-95% power).
- Balancing the image by offsetting the laser or PMT may result in a non-linear distribution of the data between each channel, hi these instances, a statistical normalization may be required. Please consult the instrument's user manual for further instructions.
- the recommended PMT settings are as follows: iitM Scanner Setting for Axon 4000B 2 Channel Scanner
- Cy is a trademark of Amersham Biosciences; Alexa Fluor is a trademark of Molecular Probes; RNeasy and Qiagen are trademarks of Qiagen Inc.; Superase-In is a trademarked product of Ambion, Inc.; Exiqon and LNA are trademarks of Exiqon A/S; Millipore, MilliQ .and. Microcon .are trademarks of Millipore, Inc.; LifterSlip is a trademark of Erie Scientific Co.; and, 3DNA, Genisphere, Array 350RP, Array 350, Array 50, Array 900 and DyeSaver are trademarks of Datascope Corp. of Montv.ale, New Jersey.
- a scaled up reverse transcription reaction can be performed from 2-50 ⁇ g of total RNA to provide extra cDNA for duplicate experiments, quantitation of the cDNA, or other parallel analysis.
- RNA-RT primer mix l-10 ⁇ l toM RNA (2-50 ⁇ g mammalian toM RNA or 25-125 ⁇ g plant toM RNA) l ⁇ l RT Primer (Vial 11, 5 pmole/ ⁇ l) Add RNase free water to a find volume of 11 ⁇ l
- RNA-RT primer mix Mix the RNA-RT primer mix and microfuge briefly to collect contents in the bottom of the tube.
- the reaction mix This is the reaction mix.
- the final volume should be 9 ⁇ l. Gently mix (do not vortex) .and microfuge briefly to collect contents in the bottom of the tube. Keep on ice until used.
- Concentration of cDNA cDNA samples may be concentrated using the Millipore Microcon YM-30 Centrifugal Filter Devices (30,000 molecular weight cutoff, Millipore caMog number 42409). These devices are capable of reducing the volume of the cDNA synthesis reaction to 3-10 ⁇ l in approximately 8-10 minutes. The procedure below reiterates the manufacturer's directions with minor adaptations for the 3DNA Array 900 Kit.
- the cDNA sample may be stored in the collection tube for later use.
- the .array is now ready for either prehybridization or hybridization with cDNA.
- Non-specific binding to the array surface is a common problem on many array types.
- the prehybridization protocol described below is recommended for reducing some types of nonspecific binding, thereby reducing the background seen post-hybridization.
- the array is now ready for hybridization with cDNA.
- Cy5/Alexa Fluor 647 dye performance may be affected by a variety of factors that are particularly prevalent during the summer months. Exposure of the Cy5/Alexa Fluor 647 dye solutions and the hybridized arrays to light and to oxidative environments may cause rapid fading of the Cy5/Alexa Fluor 647 dye, regardless of the labeling system used. Limiting or controlling the exposure of the arrays to these environments has been shown to significantly reduce Cy5/Alexa Fluor 647 fading.
- the Anti-Fade Reagent provides with the 3DNA kits.
- the Anti-Fade Reagent has anti-oxidant properties that will retard the oxidative process.
- DTT dithiothreotol
- DyeSaver Gene cat. no. Q100200
- DyeSaver is easy to use, compatible with most array surface chemistries, and protects Cy5 from atmospheric oxidation for up to three weeks.
- DyeSaver has also been shown to reduce Cy5 damage due to photobleaching.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50624703P | 2003-09-26 | 2003-09-26 | |
PCT/US2004/031804 WO2005030984A2 (en) | 2003-09-26 | 2004-09-27 | Method for small volume nucleic acid synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1664350A2 true EP1664350A2 (en) | 2006-06-07 |
EP1664350A4 EP1664350A4 (en) | 2007-10-10 |
Family
ID=34393128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04789156A Withdrawn EP1664350A4 (en) | 2003-09-26 | 2004-09-27 | Method for small volume nucleic acid synthesis |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1664350A4 (en) |
JP (1) | JP2007506439A (en) |
IL (1) | IL174486A0 (en) |
WO (1) | WO2005030984A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6692700B2 (en) | 2001-02-14 | 2004-02-17 | Handylab, Inc. | Heat-reduction methods and systems related to microfluidic devices |
US8895311B1 (en) | 2001-03-28 | 2014-11-25 | Handylab, Inc. | Methods and systems for control of general purpose microfluidic devices |
US7829025B2 (en) | 2001-03-28 | 2010-11-09 | Venture Lending & Leasing Iv, Inc. | Systems and methods for thermal actuation of microfluidic devices |
US7010391B2 (en) | 2001-03-28 | 2006-03-07 | Handylab, Inc. | Methods and systems for control of microfluidic devices |
JP4996248B2 (en) | 2003-07-31 | 2012-08-08 | ハンディーラブ インコーポレイテッド | Processing of particle-containing samples |
US8852862B2 (en) | 2004-05-03 | 2014-10-07 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
US10900066B2 (en) | 2006-03-24 | 2021-01-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US7998708B2 (en) | 2006-03-24 | 2011-08-16 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US8883490B2 (en) | 2006-03-24 | 2014-11-11 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US11806718B2 (en) | 2006-03-24 | 2023-11-07 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
DK3088083T3 (en) | 2006-03-24 | 2018-11-26 | Handylab Inc | Method of carrying out PCR down a multi-track cartridge |
WO2008061165A2 (en) | 2006-11-14 | 2008-05-22 | Handylab, Inc. | Microfluidic cartridge and method of making same |
US9618139B2 (en) | 2007-07-13 | 2017-04-11 | Handylab, Inc. | Integrated heater and magnetic separator |
US9186677B2 (en) | 2007-07-13 | 2015-11-17 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
EP3741869A1 (en) | 2007-07-13 | 2020-11-25 | Handylab, Inc. | Polynucleotide capture materials and methods of using same |
US8133671B2 (en) | 2007-07-13 | 2012-03-13 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US8105783B2 (en) | 2007-07-13 | 2012-01-31 | Handylab, Inc. | Microfluidic cartridge |
US8287820B2 (en) | 2007-07-13 | 2012-10-16 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
US8182763B2 (en) | 2007-07-13 | 2012-05-22 | Handylab, Inc. | Rack for sample tubes and reagent holders |
USD787087S1 (en) | 2008-07-14 | 2017-05-16 | Handylab, Inc. | Housing |
RU2690374C2 (en) | 2011-04-15 | 2019-06-03 | Бектон, Дикинсон Энд Компани | Scanning in real time microfluid thermal cycler and methods of synchronized thermal cycling and scanning optical detection |
CA2849917C (en) | 2011-09-30 | 2020-03-31 | Becton, Dickinson And Company | Unitized reagent strip |
USD692162S1 (en) | 2011-09-30 | 2013-10-22 | Becton, Dickinson And Company | Single piece reagent holder |
CN104040238B (en) | 2011-11-04 | 2017-06-27 | 汉迪拉布公司 | Polynucleotides sample preparation apparatus |
DK2810080T3 (en) | 2012-02-03 | 2024-06-17 | Becton Dickinson Co | External files for distribution of molecular diagnostic tests and determination of compatibility between tests |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066555A1 (en) * | 2000-03-08 | 2001-09-13 | Datascope Investment Corp. | Methods for assay and detection on a microarray |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175270A (en) * | 1986-09-10 | 1992-12-29 | Polyprobe, Inc. | Reagents for detecting and assaying nucleic acid sequences |
US5853993A (en) * | 1996-10-21 | 1998-12-29 | Hewlett-Packard Company | Signal enhancement method and kit |
US6582906B1 (en) * | 1999-04-05 | 2003-06-24 | Affymetrix, Inc. | Proportional amplification of nucleic acids |
-
2004
- 2004-09-27 JP JP2006528313A patent/JP2007506439A/en not_active Withdrawn
- 2004-09-27 WO PCT/US2004/031804 patent/WO2005030984A2/en active Application Filing
- 2004-09-27 EP EP04789156A patent/EP1664350A4/en not_active Withdrawn
-
2006
- 2006-03-22 IL IL174486A patent/IL174486A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066555A1 (en) * | 2000-03-08 | 2001-09-13 | Datascope Investment Corp. | Methods for assay and detection on a microarray |
Non-Patent Citations (1)
Title |
---|
See also references of WO2005030984A2 * |
Also Published As
Publication number | Publication date |
---|---|
IL174486A0 (en) | 2006-08-01 |
EP1664350A4 (en) | 2007-10-10 |
WO2005030984A2 (en) | 2005-04-07 |
WO2005030984A3 (en) | 2005-12-22 |
JP2007506439A (en) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1664350A2 (en) | Method for small volume nucleic acid synthesis | |
EP1438435B1 (en) | Methods for blocking nonspecific hybridisations of nucleic acid sequences | |
Xiang et al. | Amine-modified random primers to label probes for DNA microarrays | |
US20030190660A1 (en) | Compositions and methods for detecting and quantifying gene expression | |
AU2001247328B2 (en) | Methods for assay and detection on a microarray | |
AU2001247328A1 (en) | Methods for assay and detection on a microarray | |
WO2001073134A2 (en) | Gene profiling arrays | |
US20060199181A1 (en) | Compositions and methods for the treatment of immune related diseases | |
US7504209B2 (en) | Method and device for integrated nucleic acid integrity assessment and analysis | |
WO2003012147A1 (en) | Method for reusing standard blots and microarrays utilizing dna dendrimer technology | |
EP1668158A2 (en) | Rna detection and quantitation | |
US20080033159A1 (en) | Method for small volume nucleic acid synthesis | |
US20020094538A1 (en) | Methods for detecting and assaying nucleic acid sequences using temperature cycling | |
JP4840542B1 (en) | Method for preparing aRNA and analyzing gene expression | |
KR101753434B1 (en) | Method for analyzing rna | |
JP2007300829A (en) | Method for preparing specimen provided to dna microalley and the like | |
WO2002033125A1 (en) | Nucleic acid detection by dendrimeric labeling | |
Sinibaldi et al. | Gene expression analysis on medium-density oligonucleotide arrays | |
US20050202461A1 (en) | Method for converting generic nucleic acid priming sequences | |
Snijders et al. | BAC microarray-based comparative genomic hybridization | |
US20210395802A1 (en) | Inhibitor of non-specific binding of nucleic acid, hybridization reagent and nucleic acid hybridization method | |
EP1261617B1 (en) | Methods for assay and detection on a microarray | |
Kolbert et al. | Gene expression microarrays | |
WO2004061126A2 (en) | Nucleic acid hybridization assay using bridging sequence | |
Gurok et al. | Gene expression analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060310 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070906 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12M 1/36 20060101ALI20070831BHEP Ipc: C12Q 1/68 20060101ALI20070831BHEP Ipc: C07H 21/04 20060101ALI20070831BHEP Ipc: C07H 21/00 20060101AFI20070831BHEP |
|
17Q | First examination report despatched |
Effective date: 20080602 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081213 |